scholarly journals Vitamin D and Renal Disease

10.5772/64552 ◽  
2017 ◽  
Author(s):  
Jean J. Filipov ◽  
Borelli K. Zlatkov ◽  
Emil P. Dimitrov
Keyword(s):  
Vitamin D ◽  
Renal Disease

Association of Vitamin D Status With Liver and Kidney Disease: A Systematic Review of Clinical Trials, and Cross-Sectional and Cohort Studies

2019 ◽  
pp. 1-13 ◽  
Author(s):  
Seyed Mostafa Parizadeh ◽  
Majid Rezayi ◽  
Reza Jafarzadeh-Esfehani ◽  
Amir Avan ◽  
Hamideh Ghazizadeh ◽  
...  
Keyword(s):  
Vitamin D ◽  
Kidney Disease ◽  
Renal Disease ◽  
Cohort Studies ◽  
Cochrane Library ◽  
Major Public Health Problem ◽  
Vitamin D Status ◽  
Cross Sectional ◽  
Beneficial Effects ◽  
Vitamin D Levels

Abstract. Background: Vitamin D deficiency (VDD) is a major public health problem. There are few comprehensive systematic reviews about the relationship between Vitamin D status and liver and renal disease in Iran. Methods: We systemically searched the following databases: Web of Science; PubMed; Cochrane Library; Scopus; Science Direct; Google Scholar and two Iranian databases (Scientific Information Database (SID) and IranMedex) up until November 2017 to identify all randomized control trials (RCTs), case control, cross-sectional and cohort studies investigating the association between vitamin D and any form of liver or kidney disease. Results: Vitamin D insufficiency, or deficiency (VDD), is highly prevalent in Iran, reports varying between 44.4% in Isfahan to 98% in Gorgan. There is also a high prevalence of VDD among patients with liver or kidney disease, and the administration of vitamin D supplements may have beneficial effects on lipid profile, blood glucose, liver function and fatty liver disease, and bone health. Low serum vitamin D levels are related with abnormalities in these laboratory and clinical parameters. Conclusion: VDD is prevalent in patients with chronic liver or renal disease in Iran. There appear to be several beneficial effects of vitamin D supplementation in vitamin D deficient patients with liver or kidney disease.

Effect of 1,25-(OH)2D3 on jejunal absorption of magnesium in patients with chronic renal disease

1980 ◽  
Vol 238 (4) ◽  
pp. G349-G352 ◽  
Author(s):  
A. C. Schmulen ◽  
M. Lerman ◽  
C. Y. Pak ◽  
J. Zerwekh ◽  
S. Morawski ◽  
...  
Keyword(s):  
Vitamin D ◽  
Renal Disease ◽  
Chronic Renal Disease ◽  
Normal Subjects ◽  
Mean Value ◽  
Normal Serum ◽  
Perfusion Technique ◽  
Dihydroxyvitamin D3 ◽  
Jejunal Absorption ◽  
The Mean

These studies were performed to see if jejunal malabsorption of magnesium in patients with chronic renal disease was influenced by therapy with 1 alpha, 25-dihydroxyvitamin D3 [1,25-(OH)2D3; 2 microgram/day by mouth for 7 days]. This treatment restored normal serum concentrations of the vitamin D metabolite from 0.9 +/- 0.2 to 4.2 +/- 0.6 ng/dl. Jejunal absorption of magnesium, measured by a triple-lumen constant-perfusion technique, was enhanced in each of the seven patients by this therapy. The mean value rose from 0.04 +/- 0.02 to 0.13 +/- 0.02 mmol . 30 cm-1 . h-1. This last value is similar to the magnesium absorption rate in untreated normal subjects. These results demonstrate that magnesium absorption in the human jejunum is dependent on vitamin D, and they show that 1 alpha,25-dihydroxyvitamin D3 therapy in patients with chronic renal failure is associated with an enhanced jejunal absorption of magnesium.

Role of vitamin D in oxidative stress modulation in end‐stage renal disease patients: A double‐blind randomized clinical trial

2020 ◽  
Vol 24 (3) ◽  
pp. 367-373
Author(s):  
Leila Malekmakan ◽  
Zeinab Karimi ◽  
Afshin Mansourian ◽  
Maryam Pakfetrat ◽  
Jamshid Roozbeh ◽  
...  
Keyword(s):  
Oxidative Stress ◽  
Clinical Trial ◽  
Vitamin D ◽  
Renal Disease ◽  
Randomized Clinical Trial ◽  
End Stage Renal Disease ◽  
Double Blind ◽  
Stage Renal Disease ◽  
End Stage

scholarly journals P0299EVALUATION OF THE CORRELATION BETWEEN VITAMIN D LEVELS AND THROMBOCYTE MARKERS IN PATIENTS WITH DİALYSİS, CHRONIC RENAL DISEASE AND RENAL TRANSPLANTATION PATIENTS

2020 ◽  
Vol 35 (Supplement_3) ◽  
Author(s):  
KÖNÜL AHMEDOVA ◽  
Garip SAHIN ◽  
Cengiz Bal ◽  
Rüya Mutluay
Keyword(s):  
Vitamin D ◽  
Renal Transplantation ◽  
Renal Disease ◽  
Negative Correlation ◽  
Chronic Renal Disease ◽  
Significant Negative Correlation ◽  
Vitamin D Supplementation ◽  
Control Group ◽  
Before And After ◽  
Grade 3

Abstract Background and Aims 25(OH)D3 levels are known to be lower in patients with chronic renal disease (CRD). Vitamin D supplementation has been shown to have beneficial effects on mortality in these patients. In our study, we have evaluated the pleiotropic effect of vitamin D on thrombocyte markers, which is known very little by most. Method The main thrombocyte function markers (MPV, PDW and PCT) were obtained in patients which underwent dialysis, renal transplantation and patients with grade 3-4 CRD before and after vitamin D supplementation. 40 healthy individuals were chosen as control group and 24 patients underwent renal transplantation, 25 patients underwent dialysis for at least 3 months, 32 patients were diagnosed as Grade 3-4 CRD. All of the patients above had 25(OH)D3 levels <20ng/mL (<50nmol/L). Thrombocyte markers were evaluated before and after vitamin D supplementation (which was given 50.000 IU orally once a week for 8 weeks). Results Statistically no significant difference were found between MPV values in- and across- group comparison before and after vitamin D supplementation. After the correlation analyses were reviewed, statistically significant negative correlation was found (r=-0,422 p<0.05) between ΔMPV and ΔVitamin D in renal transplantation group. Also statistically significant positive correlation was found between ΔPDW and ΔVitamin D. In the control group with healty participants, a statistically significant negative correlation was found (r=-0,493 p<0.05) between ΔVitamin D and ΔThrombocyte count. In the dialysis group a statistically significant negative correlation was found (r=-0,422 p<0.05) between ΔVitamin D and ΔMPV. Conclusion A significant correlation was found particularly between Vitamin D and MPV in dialysis and renal transplantation patients. In order to prevent cardiovascular events due to thrombosis caused by Vitamin D deficiency which increases MPV, it has been thought that Vitamin D supplementation and antiaggregant therapy might be beneficial.

scholarly journals Vitamin D receptor agonist doxercalciferol modulates dietary fat-induced renal disease and renal lipid metabolism

2011 ◽  
Vol 300 (3) ◽  
pp. F801-F810 ◽  
Author(s):  
Xiaoxin X. Wang ◽  
Tao Jiang ◽  
Yan Shen ◽  
Hannah Santamaria ◽  
Nathaniel Solis ◽  
...  
Keyword(s):  
Oxidative Stress ◽  
Vitamin D ◽  
Extracellular Matrix ◽  
Growth Factors ◽  
Fatty Acid ◽  
Renal Disease ◽  
Vitamin D Receptor ◽  
Proinflammatory Cytokines ◽  
Cholesterol Synthesis ◽  
Mesangial Expansion

Diet-induced obesity (DIO) and insulin resistance in mice are associated with proteinuria, renal mesangial expansion, accumulation of extracellular matrix proteins, and activation of oxidative stress, proinflammatory cytokines, profibrotic growth factors, and the sterol regulatory element binding proteins, SREBP-1 and SREBP-2, that mediate increases in fatty acid and cholesterol synthesis. The purpose of the present study was to determine whether treatment of DIO mice with the vitamin D receptor (VDR) agonist doxercalciferol (1α-hydroxyvitamin D2) prevents renal disease. Our results indicate that treatment of DIO mice with the VDR agonist decreases proteinuria, podocyte injury, mesangial expansion, and extracellular matrix protein accumulation. The VDR agonist also decreases macrophage infiltration, oxidative stress, proinflammatory cytokines, and profibrotic growth factors. Furthermore, the VDR agonist also prevents the activation of the renin-angiotensin-aldosterone system including the angiotensin II type 1 receptor and the mineralocorticoid receptor. An additional novel finding of our study is that activation of VDR results in decreased accumulation of neutral lipids (triglycerides and cholesterol) and expression of adipophilin in the kidney by decreasing SREBP-1 and SREBP-2 expression and target enzymes that mediate fatty acid and cholesterol synthesis and increasing expression of the farnesoid X receptor. This study therefore demonstrates multiple novel effects of VDR activation in the kidney which prevent renal manifestations of DIO in the kidney.

Sign in / Sign up

Export Citation Format

Share Document